Elite files abbreviated new drug application for pain reliever
Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A
Commercial Banking: June 22nd Edition
Understanding Loss Given Default A Review of Three Approaches
Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy
Elite Pharmaceuticals Inc. submitted an abbreviated new drug application to the U.S. FDA for a generic version of Norco, a pain relief drug.
According to IMS Health data, total annual U.S. sales for combination products of hydrocodone and acetaminophen are about $700 million.